ERRATUM

Erratum to: Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)

Eiji Oki, MD, PhD, FACS¹, Yasunori Emi, MD, PhD², Yuji Miyamoto, MD, PhD³, Akira Kabashima, MD, PhD⁴, Hidefumi Higashi, MD, PhD⁵, Yutaka Ogata, MD, PhD⁶, Masahiko Ikebe, MD, PhD⁷, Hiroshi Saeki, MD, PhD, FACS¹, Shoji Tokunaga, PhD⁸, Ken Shirabe, MD, PhD, FACS¹, Toru Beppu, MD, PhD³, Shinji Uchida, MD, PhD⁶, Mitsuhisa Takatsuki, MD, PhD⁹, Masahiko Sakoda, MD, PhD¹⁰, Susumu Eguchi, MD, PhD, FACS⁹, Yoshito Akagi, MD, PhD¹¹, Yoshihiro Kakeji, MD, PhD, FACS¹², Hideo Baba, MD, PhD, FACS³, Shoji Natsugoe, MD, PhD¹⁰, Yoshihiko Maehara, MD, PhD, FACS¹ and Kyushu Study Group of Clinical Cancer (KSCC)

¹Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;

²Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan; ³Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; ⁴Department of Surgery, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan; ⁵Department of Surgery, Steel Memorial Yawata Hospital, Kitakyushu, Japan; ⁶Department of Surgery, Kurume University Medical Center, Kurume, Japan; ⁷Department of Gastroenterological Surgery, Beppu Medical Center, Beppu, Japan; ⁸Medical Information Center, Kyushu University Hospital, Fukuoka, Japan; ⁹Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; ¹⁰Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; ¹¹Department of Surgery, Kurume University School of Medicine, Kurume, Japan; ¹²Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan

ERRATUM TO: ANN SURG ONCOL DOI 10.1245/S10434-015-4771-1

In first sentence of the Protocol Treatment section on the second page of the original article there is an error in the oxaliplatin dosage. The corrected sentence is as follows: In principle, 4–6 cycles of preoperative chemotherapy—SOX: S-1 is orally administrated at a dose corresponding to the

body surface area (BSA) (40 mg with BSA < 1.25 m²; 50 mg with BSA 1.25–1.50 m²; 60 mg with BSA > 1.50 m²) twice daily after meals for 14 consecutive days, oxaliplatin (130 mg/m²) day 1 every 3 weeks, plus cetuximab (400 mg/m² as the initial dose) followed by 250 mg/m²/week—was administered within 2 weeks after enrollment.

The online version of the original article can be found under doi:[10.1245/s10434-015-4771-1](https://doi.org/10.1245/s10434-015-4771-1).

© Society of Surgical Oncology 2015

Published Online: 21 Sep 2015

E. Oki, MD, PhD, FACS

e-mail: okieiji@surg2.med.kyushu-u.ac.jp